Oxford Science Enterprises

🎬 “You’ve got that great combination of deep science and technology backing a business that can become commercial”   The UK’s universities are home to world-class research in science and technology. Their spin-outs are potentially the world-leading businesses of tomorrow tackling global challenges whether related to heath, climate change, food security or the transition to quantum computing.   What makes them an attractive asset class for institutional investors? We asked Ben Luckett of Aviva Investors at the first Oxford Science Enterprises, Cambridge Innovation Capital and Northern Gritstone joint investor event showcasing UK universities as an asset class.    Watch the full film below.

🎥 Catch our CEO Edward Bussey speaking at this week's #BloombergTech Summit on how investors are approaching sustainability practises when building the next-generation of innovative companies. Full clip below ⤵️ https://lnkd.in/dfn_JWME

Yesterday our CEO Edward Bussey spoke at the Bloomberg Live Tech London Summit on a panel moderated by Bloomberg Tech Editor Olivia Solon, alongside Dr Mohsin Pirzada, Qatar Investment Authority and Daria Saharova, World Fund . The discussion focused on the intersection of technology and sustainability, looking at how investors are approaching ESG and impact practises with a forward-looking lens on the technologies that are set to define the future. At OSE our mission is to build companies solving the world’s greatest challenges. Sustainability practises aren’t a box to check; they’re fundamental to both OSE and our portfolio companies’ long-term success. Watch the full session here: https://lnkd.in/dfn_JWME #BloombergTech #innovation #sustainability #ESG #impact (Photo credit: Bloomberg)

Earlier this month, OSE’s Edward Bussey and Jack Edmondson visited Culham Campus to see firsthand the incredible innovation happening at the UK Atomic Energy Authority (UKAEA). A big thank you to Tim Bestwick and the team for the insightful tour and discussions! Oxford Science Enterprises is committed to advancing technologies that will transform industries, and the work being done at Culham is at the forefront of that mission. #Innovation #OxfordScience #FutureofEnergy

🎥 Spotlight on our portfolio company Nucleome Therapeutics via BiotechTV. 🔬 Nucleome Therapeutics is pioneering the use of cutting-edge 3D genome sequencing and AI to unlock the "dark genome"—the 98% of our DNA that’s not truly understood but holds immense potential. By decoding these hidden genetic drivers, Nucleome is designing groundbreaking therapies to tackle inflammatory diseases and beyond. 📺 Watch the full interview with Nucleome's CEO Mark Bodmer, who breaks down the company’s innovative approach:

🌍 We had the pleasure of hosting a productive and thought-provoking discussion at the Saïd Business School, University of Oxford last week, all on ESG!   Chaired by our brilliant Emily Matthews, who heads up OSE’s Responsible Investment, we welcomed over 20 of the brightest minds from VCs, LPs, sustainability consultancies, and portfolio companies to discuss ESG Strategies for startups.   The roundtable explored investor approaches to assessing and engaging on ESG, the evolving landscape, and real-world examples of best practices across sectors and stages.   Key takeaways from the session included: 📈 That sustainability is a journey – The importance of getting started early, how to best identify and prioritise material topics, and why the focus should be on “progress over perfection”. 📊Finding the overlap – Key focus areas discussed that intersect across sectors, stages, and stakeholders including sustainability governance, climate, diversity & inclusion, and cybersecurity. 🔓 Unlocking value – Why sustainability integration enables access to both capital and revenue, and how it creates an opportunity to enhance employee engagement.   A big thank you to all the fantastic contributors in the room. We’re excited to continue driving meaningful conversations around ESG and its role in shaping the next generation of transformational businesses.   #innovation #ESG #UniversitySpinouts

💡Our CEO Edward Bussey joined Bloomberg Radio this morning to discuss key takeaways from yesterday's government hosted International Investment Summit. Ed discussed how the summit underscored the UK’s commitment to being open for business, but emphasised the need for a joined-up government and industry led strategy that turns ambition into action. 🎧 Listen to the full interview here: https://lnkd.in/eDSMbtqR

What an excellent turnout at Wednesday's investor event! We were thrilled to welcome, alongside Cambridge Innovation Capital and Northern Gritstone, over 300 institutional investors, including Mansion House signatories, pension funds, global venture investors, asset managers, and UK policymakers.   The energy in the room was palpable, as we showcased groundbreaking innovations from UK university spin-outs and explored the vast investment potential in Life Sciences, Health Tech, and Deep Tech.    A big thank you to all of our sponsors, speakers, panellists, and attendees for making it a success!   Here’s to driving the future of UK innovation together ⚡ British Business Bank, City of London Corporation, Innovate UK, Global Corporate Venturing, PwC, Taylor Wessing UK   Sir Nicholas Lyons, Nicola Blackwood, Louis Taylor, Scott James O'Brien, Edward Bussey, Heather Roxborough, Ben Luckett, Optalysys, adsilico Limited, Sheena Macpherson, Nick New, Vaysh Kewada, Salience Labs, Allan Bradley, T-Therapeutics Ltd, Aidan Crawley, Amber Therapeutics, Ros Deegan, OMass Therapeutics, Andrew Williamson, Duncan Johnson, Anne Horgan (nee Nguyen), Marion Bernard, Anna Dickinson #UKspinouts, #Innovation, #healthtech #LifeSciences #DeepTech

Today we're excited to announce that we're co-hosting our first combined investor event alongside Cambridge Innovation Capital and Northern Gritstone! This event showcases some of the most groundbreaking innovations from UK university spin-outs, and we're thrilled to highlight the incredible investment opportunities within the UK's thriving innovation ecosystem. With insightful presentations from leading figures such as Lord Jim O’Neil, Sir Nicholas Lyons, Baroness Nicola Blackwood, Louis Taylor of British Business Bank, Scott James O'Brien of Innovate UK and Ben Luckett of Aviva, as well as pitches from visionary founders in Life Sciences, Health Tech, and Deep Tech. With special thanks to our sponsors City of London Corporation, British Business Bank, Innovate UK, Global Corporate Venturing, Taylor Wessing, PwC, and to all of our speakers Duncan Johnson, Andrew Williamson, Heather Roxborough, Aidan Crawley of Amber Therapeutics, Sheena Macpherson of adsilico Limited, Marion Bernard, Vaysh Kewada of Salience Labs, Nick New of Optalysys, Anne Horgan (nee Nguyen), Allan Bradley of T-Therapeutics Ltd, Ros Deegan of OMass Therapeutics and Edward Bussey. Let’s invest in tomorrow’s global success stories, today. #UKspinouts #UKInnovation #InvestingInTheFuture #UniversitySpinouts #LifeSciences #DeepTech #entrepreneurship #impact

Our CEO Edward Bussey recently sat down with Quad, Oxford's Alumni Magazine, to reflect on his journey since joining OSE one year ago and share his vision for the future. In the interview, Ed discusses his perspective on the unique opportunity that comes with leading OSE, busts common myths about what we do, and highlights the company's critical role in shaping the next generation of transformational businesses. His vision for the future of innovation in the UK calls for the unlocking of more scale-up capital (via Mansion House Compact), greater collaboration between industry and government, and moving at 10x the speed to maximise the crucial role that spinout companies have in supporting the country's economic growth and productivity. 🔗 Read the full interview, written by Richard Lofthouse here- https://lnkd.in/efmwxbDG #Leadership #Innovation #OxfordAlumni #OxfordInnovation